



Role of NO in Disease: Good, Bad or Ugly

Guest Editors:

Dr. Mats B. Eriksson

Department of Surgical Sciences,
Anaesthesiology and Intensive Care
Medicine, Uppsala University, 751
85 Uppsala, Sweden

Prof. Dr. Anders O. Larsson

Department of Medical Sciences,
Clinical Chemistry, Uppsala
University, 751 85 Uppsala,
Sweden

Deadline for manuscript
submissions:

31 May 2024

Message from the Guest Editors

L-Arginine is a precursor for NO synthesis. NO is a reactive molecule with unpaired electrons, being a ubiquitous signaling molecule, able to interact with molecular oxygen and superoxide radicals. Endothelial cells are the largest source of NO production.

The antiviral effects of NO have caused considerable interest during the COVID-19 pandemic. NO impedes the binding of SARS-CoV-2 to the ACE2 receptor and counteracts viral replication. Compromised production or bioavailability of NO is associated with both arterial and venous thrombi, a frequent consequence of COVID-19.

Given the multitude of powerful biological effects of NO, several attempts have been made to utilize this radical as a therapeutic agent, mainly in pulmonary hypertension. Administration of NO has focused on inhalation, which may cause the relaxation of smooth muscle cells in the pulmonary vasculature. Vasodilation results in improved perfusion to ventilated areas of lung, thereby improving oxygenation and reducing intrapulmonary shunting.

However, NO is potentially harmful, since its oxidation products are toxic and may contribute to tissue damage in certain disorders.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)